Author

Lucas Baldran-Groves

Karolinska InstitutetORCID 0009-0006-5555-378XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:imaging· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

Alireza AzimiiD· 1 shared Andreas LundqvistiD· 1 shared Andreas ParlingiD· 1 shared Fan ZhangiD· 1 shared Fredrik Jerhammar· 1 shared Galina SelivanovaiD· 1 shared Hanna van OoijeniD· 1 shared Ishani DasiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alireza AzimiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintOct 30, 2026

CD4 T cell surface architecture is associated with response to anti-PD-1 therapy in non-small cell lung cancer

Riccardo Cinotti, Ying Yang, Vincent van Hoef…·Andreas Lundqvist

The paper shows that CD4 T cell surface protein organization predicts response to anti-PD-1 therapy in NSCLC, outperforming protein abundance alone.

DOI 10.64898/2026.10.26.761814

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 4, 2025

Palbociclib CDK4/6- and Crizotinib MET/ALK/ROS1-inhibitors Synergize to Enhance Senescence and Immune Recognition in Melanoma Cells Independently of BRAF/NRAS Status

Fan Zhang, Lola Boutin, Ishani Das…·Lars‐Gunnar Larsson

This study shows that combining palbociclib and crizotinib enhances senescence and immune recognition in melanoma cells regardless of BRAF/NRAS status, reducing tumor growth.

DOI 10.1101/2025.07.04.663080

𝕏 PostBluesky